Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to assess the drug absorption of oral antibiotics in patients with short bowel syndrome.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Short bowel syndrome
• Treated for a documented infection with antibiogram by amoxicillin (+/- clavulanic acid)or ofloxacin or levofloxacin or sulfamethoxazole/trimethoprim
• Hospitalized in the Nutritional Assistant Unit or the Infectiology Unit of the Regional University Hospital of Nancy
• Affiliated to a social security system
• Having received an physical examination before entering study
• Having received full information regarding the study organization and having signed the informed consent
Locations
Other Locations
France
CHRU Nancy
RECRUITING
Vandœuvre-lès-nancy
Contact Information
Primary
Niasha MICHOT, MD
n.michot@chru-nancy.fr
+33383155108
Backup
Elise Pape
e.pape@chru-nancy.fr
Time Frame
Start Date: 2022-12-09
Estimated Completion Date: 2025-02
Participants
Target number of participants: 10
Treatments
Experimental: Amoxicillin
Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
Experimental: Ofloxacin
Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
Experimental: Levofloxacin
Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
Experimental: Sulfamethoxazole trimethoprim
Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.
Related Therapeutic Areas
Sponsors
Collaborators: Fresenius Kabi, Société Francophone Nutrition Clinique et Métabolisme, FIlière des Maladies rares Abdomino-THOraciques
Leads: Central Hospital, Nancy, France